Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Merck Sharp + Dohme Corp.

Ra Pharmaceuticals, Inc.

Stefania Colarusso

Frank Narjes

Simona Ponzi

Immacolata Conte

Thomas Joseph Tucker

Alonso Ricardo

Elisabetta Bianchi

Yusheng Xiong

Eric J Gilbert

Mark W Embrey

Sookhee Nicole Ha

Nicolas Cedric Boyer

Angela Dawn Kerekes

Raffaele Ingenito

Joerg Habermann

Aurash Shahripour

Danila Branca

Hyewon Youm

Chengwei Wu

Alessia Santoprete

Willy Costantini

Joseph R Stringer

Derek M LaPlaca

Roberto Costante

Alessia Petrocchi

Uwe Koch

Steven Harper

Jesus Maria Ontoria Ontoria

Ester Muraglia

Cristina Gardelli

Ian Stansfield

Victor Giulio Matassa

Maria Del Rosario Rico Ferreira

Benjamin Gerlach

Vicenzo Summa

Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.

Cyclic polypeptides for PCSK9 inhibition

The present invention relates to tetracyclic thienopyrrole compounds of formula (I), wherein Ar, A, D1, D2, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus. 

Thienopyrroles as antiviral agents

The present invention relates to indole compounds of the formula (I): wherein R, R, R, R, A, E and X are as defined herein, and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C infections. 

Indole derivatives as antiviral agents

Compounds of formula (I), and pharmaceutically acceptable salts and esters thereof: (I); wherein Q, R2, X, Y and Z are as defined herein; are inhibitors of the hepatitis C virus (HCV) NS3 protease 

Peptides and their use as inhibitors of hepatitis C virus ns3 protease

Growing community of inventors

Rome, Italy

Stefania Colarusso